An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Status:
Active, not recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the objective response rate of parsaclisib treatment
in subjects with relapsed or refractory follicular lymphoma.